Adial Pharmaceuticals (ADIL) Revenue & Revenue Breakdown
Adial Pharmaceuticals Revenue Highlights
Adial Pharmaceuticals Revenue by Period
Adial Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Adial Pharmaceuticals generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Adial Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $32.25K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | - |
Adial Pharmaceuticals generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Adial Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ONTX | Traws Pharma | $226.00B | $56.00K |
| TNXP | Tonix Pharmaceuticals | $7.77M | $2.21M |
| AEZS | Aeterna Zentaris | $4.58M | $3.98K |
| CBIO | Gyre Therapeutics | $794.00K | - |
| ADTX | Aditxt | $645.18K | $44.28K |
| BNTC | Benitec Biopharma | $75.00K | $6.00K |
| VRAX | Virax Biolabs Group | $8.56K | $76.50K |
| NRBO | NeuroBo Pharmaceuticals | $7.00K | - |
| BPTH | Bio-Path | - | - |
| RVPH | Reviva Pharmaceuticals | - | - |
| REVB | Revelation Biosciences | - | - |
| ALRN | Aileron Therapeutics | - | - |
| ADIL | Adial Pharmaceuticals | - | - |
| RNXT | RenovoRx | - | - |
| AXLA | Axcella Health | - | - |
| HOTH | Hoth Therapeutics | - | - |
| ATXI | Avenue Therapeutics | - | - |
| RNAZ | TransCode Therapeutics | - | - |
| DFFN | CervoMed | - | - |
| KTTA | Pasithea Therapeutics | - | - |
ADIL Revenue FAQ
What is Adial Pharmaceuticals’s yearly revenue?
Adial Pharmaceuticals's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. ADIL's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Adial Pharmaceuticals’s quarterly revenue?
Adial Pharmaceuticals's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $32.25K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). ADIL's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Adial Pharmaceuticals’s revenue growth rate?
Adial Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.